ALASTIN Restorative Skin Complex: Seven Peptides in a Row, and a "Facial Fat" Claim the Wider Literature Reads the Other Way

Restorative Skin Complex is the daily serum in ALASTIN's line, sold mainly through dermatology and aesthetic practices at $258 an ounce. ALASTIN, now a Galderma company, has put its own peptide system into the journals: 20 PubMed records name Alastin in the title or abstract. That makes this product unusually checkable: there is a full ingredient list on the product page, and there are papers. This page reads both, as served on 6 October 2026. It gives the serum no grade and makes no buying call.

The list: seven peptides in an unbroken run

ALASTIN's page declares 50 ingredients. The first 16, which carry everything the brand names as active, are:

Positions 17 to 50 hold ceramides, ergothioneine, algae and mushroom extracts, lipids, emulsifiers, pH adjusters and a preservative system ending in phenoxyethanol.

Seven peptides back to back is a long run for one list. Unlike the headline count on the Drunk Elephant Protini analysis, which has to be decomposed before it means anything, this one holds up: each of the seven is a distinct declared peptide. What the list does not do is say how much of any of them is present. US rules let anything at 1% or less be listed in any order (21 CFR 701.3(f)(2)), and the label gives no concentrations, so the position of the seven, just below a thickener and a solvent, says nothing firm about their amounts.

The two peptides with a file of their own

Positions 7 and 8 are the pair ALASTIN calls TriHex: tripeptide-1 and hexapeptide-12. This journal has a full TriHex entry that counts the pair's literature, its designs and who funded it, and it is not repeated here. One detail on this label differs from that entry, which describes the TriHex pair without a fatty-acid tail: while this list declares both in their palmitoyl forms, which are different molecules on paper. The short version that matters for this page: the TriHex literature is large for a cosmetic peptide, built mostly around recovery after procedures, and funded by the company. Each peptide also has its own spoke — palmitoyl tripeptide-1 and palmitoyl hexapeptide-12 — for readers who want the molecules separately.

Position 9, palmitoyl tripeptide-5, is the peptide sold to formulators as Syn-Coll. Our palmitoyl tripeptide-5 file traces its sequence and the human evidence behind it.

The three that are harder to look up

The two dipeptide-5 derivatives (positions 10 and 11) are long chemical names for modified two-residue peptides. A PubMed search for "palmitoyl dipeptide-5" returned a phrase-not-found warning on 6 October 2026, which means the count is unknown, not zero: PubMed did not recognise the phrase at all.

Acetyl hexapeptide-38 (position 12) is a quoted-phrase trap. Searched as a quoted phrase, PubMed reported it as not found. Searched as hexapeptide-38 in title or abstract, it returned one record: a 2026 case report from Chile of a woman with chronic facial paralysis, treated with a cannula technique plus injected DMAE, organic silicon and acetyl hexapeptide-38 (Calfin 2026). That is one person, three agents, an injection rather than a cream and a different purpose. It is the whole indexed human record for the ingredient.

Octapeptide-45 (position 13) is the newest and the most closely held. Its developers describe it as "proprietary, patent-pending" (Widgerow 2025, TriHex 2.0). On 6 October 2026, PubMed held four records naming it; every one has authors employed by, or consulting for, Alastin or Galderma. The founding paper tested it on skin explants in the laboratory, reporting more hyaluronic-acid staining (160% above untreated tissue) when it was added to TriHex, and closes with "Clinical studies to follow." Nobody outside the company has yet published on the molecule.

What the one trial of this formula tested

The reformulated serum — ALASTIN's papers call it Restorative Skin Complex 2.0, with octapeptide-45 and magnolol added — has one published clinical trial (Gold 2025):

Three features limit what it can show. With no control group, the study cannot separate the serum from the season, the attention of being in a trial, or the supportive products used beside it. With an open label, participants and graders knew what was being used. And because the full regimen was used, the trial tests a routine, not the serum alone — and certainly not any single peptide in it.

The product page's own consumer figures — 98% agreed it improved hydration, 89% reported better texture, 93% were satisfied, "in as early as 12 weeks" — are self-assessments. The page does not cite the study they come from. The 12-week duration matches Gold 2025, but this page could not confirm they are the same study.

The magnolol claim, set beside the wider literature

ALASTIN's key-ingredients panel says magnolol "helps support the body's natural production of healthy facial fat (adipose tissue)", and the product description promises "visible, long-term volumization to thinning skin". The maker's trial supports this from inside: its biopsies were read as showing "increased stimulation of new adipocytes".

The independent literature on magnolol and fat mostly runs the other way. A 2024 study of magnolol and honokiol in mice on a high-fat diet reported that both "promote adipose tissue browning and resist obesity" (Chu 2024). A second 2024 study of Magnolia officinalis extract, which contains magnolol and honokiol, reported that lipid droplets and fat-forming genes "were notably diminished" in fat cells and proposed the extract for treating obesity (Park 2024). Neither tested skin, a cream or the face, so neither disproves ALASTIN's finding. But a reader who looks magnolol up will mostly find it studied as an anti-obesity compound, and the only work showing it building fat in skin is the maker's.

There is also a regulatory edge. Under the US Federal Food, Drug, and Cosmetic Act, a product "intended to affect the structure or any function of the body" meets the definition of a drug, and FDA states that whether a product is a cosmetic or a drug is decided by its intended use (FDA, "Is It a Cosmetic, a Drug, or Both?"). A claim to support the production of fat tissue is a structure claim in plain words. This page reports where the wording sits; whether it crosses the line is for a regulator, not for us.

For and against, on the label's own terms

For: the full list is published on the product page; seven distinct peptides are declared and the count holds up when checked; the maker has published its laboratory and clinical work rather than citing data only "on file"; niacinamide sits at position 3.

Against: no concentrations; the one trial of this formula is open-label, uncontrolled and run with the maker's full regimen; every paper on octapeptide-45 comes from the company; two of the seven peptides could not be searched by name in PubMed and a third has a single unrelated case report; the volume claim rests on maker-run biopsies while independent animal work on magnolol points the other way; and at $258 an ounce, none of this can be weighed against a test of the finished serum by anyone outside the company.

What the label settles, and what it does not

It settles the list: 50 ingredients, niacinamide at 3, seven peptides at 7 to 13, magnolol at 15. It settles that the published trial of this formula is a 44-person open-label study run with the maker. It does not settle how much of any peptide is in the bottle, whether the serum does anything the regimen around it would not, or whether magnolol on facial skin builds fat in anyone outside the maker's biopsies.

Sources

• ALASTIN Skincare, Restorative Skin Complex with TriHex+, alastin.com product page and its Shopify product record: full ingredient list (50 items), key-ingredient claims, consumer percentages and price ($258 / 1.0 fl oz). Fetched with plain curl and read 2026-10-06; the product title matched.
• Gold M, Boyd C, Mraz D, Robison T, Shafiq F, Widgerow AD. A multi-center clinical trial to evaluate the efficacy of the next generation TriHex Technology antiaging regimen. J Cosmet Dermatol 2025;24(4):e70192. PMID 40280771. Conflict-of-interest statement read.
• Widgerow AD, Ziegler ME, Shafiq F. TriHex 2.0 — advancing skin health science and the TriHex technology. J Cosmet Dermatol 2025;24(2):e16690. PMID 39660586.
• Widgerow AD, et al. Pre-conditioning with a TriHex Technology serum (Nectar 2.0) versus vehicle before facelift surgery, 5 patients. J Cosmet Dermatol 2025;24(12):e70599. PMID 41358458; and Jalian HR, et al. J Cosmet Dermatol 2025;24(12):e70556. PMID 41293824 — the other two octapeptide-45 records (a different ALASTIN product).
• Chu Y, et al. The natural compounds, magnolol or honokiol, promote adipose tissue browning and resist obesity through modulating PPARα/γ activity. Eur J Pharmacol 2024;969:176438. PMID 38402928.
• Park YJ, et al. Magnolia officinalis ameliorates white adipogenesis by upregulating AMPK and SIRT1 in vitro and in vivo. Heliyon 2024;10(6):e27600. PMID 38515723.
• Calfin H, et al. Facial adipostructuring with biochemical modulation in chronic peripheral facial paralysis: a case report. Cureus 2026;18(6):e111350. PMID 42344748.
• US Food and Drug Administration, Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?), read 2026-10-06; FD&C Act section 201(g)(1). 21 CFR 701.3(f)(2).
• PubMed E-utilities searches, 2026-10-06, quotedphrasesnotfound read on each: octapeptide-45[tiab] (4); "acetyl hexapeptide-38"[tiab] (phrase not found) and hexapeptide-38[tiab] (1); ("palmitoyl dipeptide-5" OR syn-tacks) (phrase not found — count unknown); magnolol AND (adipocyte* OR adipogen*) (18); alastin[tiab] (20) and with the randomized-trial filter (8); (alastin[tiab] OR trihex[tiab]) AND Retracted Publication[pt] (0). Control: retinol AND skin AND "randomized controlled trial"[pt] (334).